Amgen backs US$30 million Series A for AI genetic testing

Amgen, a large US biopharmaceutical group, has leaned further into AI-driven precision medicine by backing Arboretum LifeSciences. The US$30 million Series A round is focused on applying AI-driven genetic testing and molecular data tools to support more targeted healthcare decisions. For Amgen, this move plugs directly into its core drug research engine, as the group focuses on discovering and delivering human therapeutics worldwide.

The funding round reinforces the part of Amgen's narrative that depends on personalized and targeted therapies across cardiometabolic disease, oncology and rare disorders. It lines up with the existing catalyst that personalized treatments and genomically guided trials can help sustain a diversified earnings profile as older products face loss of exclusivity and pricing pressure. It also speaks to the bear concern that Amgen must keep refreshing its pipeline for the current bullish narrative on its broad portfolio to hold together.

Whether this funding translates into tangible pipeline progress hinges on Amgen's ability to integrate Arboretum's molecular insights into its trial designs and patient selection. For investors, the key test will be whether the company discloses genomically stratified data for programs like MariTide, Repatha, or its bispecific oncology drugs, which would signal that the collaboration is yielding concrete results.